902 KAR 55:025.
Schedule III substances.
RELATES TO: KRS
218A.010-218A.030, 218A.080, 218A.090, 21 C.F.R. 1308.13, 21 U.S.C. 801, 812
STATUTORY
AUTHORITY: KRS 218A.020
NECESSITY,
FUNCTION, AND CONFORMITY: KRS 218A.020 authorizes the Cabinet for Health
Services to add, delete, or reschedule substances enumerated in KRS Chapter
218A. This administrative regulation designates Schedule III controlled
substances.
Section 1.
Amphetamine and Methamphetamine Combination Products. The Cabinet for Health
Services designates the following amphetamine and methamphetamine combination
products as Schedule III Controlled Substances:
(1) A tablet or
capsule containing:
(a)
Methamphetamine hydrochloride 1 mg.;
(b) Conjugated
estrogens-equine 0.25 mg.; and
(c) Methyl
testosterone 2.5 mg; and
(2) A liquid
containing, in each 15 cc:
(a)
Methamphetamine hydrochloride 1 mg.;
(b) Conjugated
estrogens-equine 0.25 mg.; and
(c) Methyl
testosterone 2.5 mg.
Section 2.
Stimulants. The Cabinet for Health Services designates as Schedule III
controlled substances a material, compound, mixture, or preparation which
contains any quantity of the following substances having a stimulant effect on
the central nervous system, including their salts, isomers (whether optical
position or geometric), and salts of those isomers if the existence of the
salts, isomers or salts of isomers is possible within the specific chemical
designation:
(1)
Benzphetamine;
(2)
Chlorphentermine;
(3)
Chlortermine; and
(4)
Phendimetrazine.
Section 3.
Depressants. The Cabinet for Health Services designates as Schedule III
controlled substances the following:
(1) A material,
compound, mixture, or preparation containing amobarbital, secobarbital, or
pentobarbital, or any of their salts, and at least one (1) other active
medicinal ingredient which is not a controlled substance;
(2) A
suppository dosage form containing amobarbital, secobarbital, or pentobarbital,
or any of their salts, which has been approved by the United States Food and
Drug Administration for marketing only as a suppository;
(3) A drug
product containing gamma-hydroxybutyric acid, including its salts, isomers, and
salts of isomers, for which an application is approved under section 505 of the
Federal Food, Drug, and Cosmetic Act, 21 USC Chapter 9. Gamma hydroxybutyric
acid is also known as:
(a) GHB;
(b)
Gamma-hydroxybutyrate;
(c)
4-hydroxybutyrate;
(d)
4-hydroxybutanoic acid;
(e) Sodium
oxybate; or
(f) Sodium
oxybutyrate;
(4) Ketamine,
its salts, isomers, and salts of isomers. Ketamine is also known as (±)-2-(2-chlorophenyl)-2-(methylamino)-cyclhexanone;
and
(5) Tiletamine
and zolazepam or any of their salts.
(a) Tiletamine
is also known as 2-(ethylamino)-2-(2-thienyl)-cyclohexanone.
(b) Zolazepam is
also known as 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-(3,4-e)
(1,4)-dizepin-7(1H)one, flupyrazpon.
Section 4.
Pentazocine Drug Products. The Cabinet for Health Services designates, in
addition to the parenteral or injectable form of Pentazocine which is
designated as a Schedule III controlled substance by KRS 218A.090(3), a
material, compound, mixture, or preparation which contains a quantity of
Pentazocine, including its salts.
Section 5.
Anabolic Steroids. The Cabinet for Health Services designates as Schedule III
Controlled Substances, in addition to those listed in KRS 218.090(5), a
material, compound, mixture, or preparation which contains a quantity of the
following substances, including its salts, isomers, and salts of isomers, if
the existence of salts of isomers is possible within the specific chemical
designation:
(1)
Chlorotestosterone;
(2)
Dihydrotestosterone; and
(3)
Methandranone.
Section 6.
Hallucinogenic Substances. The Cabinet for Health Services designates as
Schedule III controlled substances, in addition to those listed in KRS
218A.090, a material, compound, mixture, or preparation which contains a
quantity of dronabinol (synthetic) in sesame oil and encapsulated in a soft
gelatin capsule in a U.S. Food and Drug Administration approved product.
Dronabinol is also known as:
(1) (6aR-trans)-6a, 7, 8, 10a-
tetrahydro-6, 6, 9-trimethyl-3-pentyl-6H-dibenzo{b,d}pyran-1-ol; or
(2) (-)- delta-9-(trans)-
tetrahydrocannabinol.
Section 7. Narcotics. The Cabinet for
Health Services designates as Schedule III controlled substance a material,
compound, mixture, or preparation which contains any quantity of buprenorphine,
or its salts. (Recodified from 901 KAR 1:025, 4-14-82; Am. 11 Ky.R.
1676; eff. 6-4-85; 13 Ky.R. 1946; eff. 6-9-87; 15 Ky.R. 865; eff. 11-4-88; 17
Ky.R. 3283; eff. 6-19-91; 20 Ky.R. 861; eff. 12-6-93; 26 Ky.R. 1238; 1562; eff.
2-1-2000; 29 Ky.R. 817; 1277; eff. 10-16-02.)
